Source comparison
Peptides for Sexual Performance: Research-Grade vs FDA-Approved Comparison
PT-141 (Bremelanotide) MC3R/MC4R melanocortin receptor agonist in hypothalamus. Central arousal pathway activation Phase 3 RCT (n=1,267) showed 52% response rate vs 32% placebo for HSDD in premenopausal women; FDA-approved 2019 Subcutaneous injection 1.75mg pr
This comparison does not assign a generated winner or score.
- PT-141 (Bremelanotide)
- MC3R/MC4R melanocortin receptor agonist in hypothalamus. Central arousal pathway activation
- Phase 3 RCT (n=1,267) showed 52% response rate vs 32% placebo for HSDD in premenopausal women; FDA-approved 2019
- Subcutaneous injection 1.75mg pre-activity
- FDA-approved as Vyleesi; compounded versions available from 503B facilities
- Strongest evidence base for central desire pathways. Not a vascular mechanism
- Ipamorelin + CJC-1295
- Growth hormone secretagogue. Stimulates pituitary GH release, elevates IGF-1 over weeks
- Observational studies only; no RCTs isolating sexual function endpoints
- Subcutaneous injection daily or 3–5x weekly
- Research-grade only. Not FDA-approved for any indication
- Indirect mechanism through metabolic optimization. Requires 8–12 week cycles
- Hexarelin
- Ghrelin receptor agonist + GH secretagogue. Cardioprotective + IGF-1 elevation
- Small cohort studies (n<50) showing endothelial function improvements; no sexual performance RCTs
- Subcutaneous injection 100–200mcg daily
- Research-grade only
- Plausible vascular benefit but zero direct sexual function data
- Modified GHK-Cu Analogs
- VEGF upregulation + angiogenesis. Theoretical vascular remodeling in penile tissue
- Wound healing and dermatology studies only; no sexual function trials
- Subcutaneous injection or topical
- Biologically plausible but entirely speculative for sexual performance
- Kisspeptin-10
- Hypothalamic kisspeptin receptor agonist. Upstream regulator of GnRH and LH/testosterone pathways
- Phase 1 trials (n=29 men) showed increased LH pulse frequency but no sexual function endpoints
- Intravenous infusion in trials; subcutaneous for research
- Interesting neuroendocrine mechanism but no practical sexual performance data